124 related articles for article (PubMed ID: 37328387)
21. CA19-9 Reduction After 4 Months of Treatment Is a Prognostic Factor for Locally Advanced Pancreatic Cancer.
Mie T; Ozaka M; Okamoto T; Takeda T; Ushida Y; Mori C; Furukawa T; Yamada Y; Kasuga A; Matsuyama M; Sasaki T; Inoue Y; Takahashi YU; Sasahira N
In Vivo; 2022; 36(6):2844-2851. PubMed ID: 36309391
[TBL] [Abstract][Full Text] [Related]
22. The impact of early tumor shrinkage on conversion surgery and the survival in patients with unresectable locally advanced pancreatic cancer.
Takano N; Yamada S; Sonohara F; Inokawa Y; Takami H; Hayashi M; Koike M; Fujii T; Kodera Y
Surg Today; 2021 Jul; 51(7):1099-1107. PubMed ID: 33483785
[TBL] [Abstract][Full Text] [Related]
23. Carbohydrate antigen 242 highly consists with carbohydrate antigen 19-9 in diagnosis and prognosis of colorectal cancer: study on 185 cases.
Yang XQ; Chen C; Peng CW; Liu SP; Li Y
Med Oncol; 2012 Jun; 29(2):1030-6. PubMed ID: 21553105
[TBL] [Abstract][Full Text] [Related]
24. Utility of tumor markers in determining resectability of pancreatic cancer.
Schlieman MG; Ho HS; Bold RJ
Arch Surg; 2003 Sep; 138(9):951-5; discussion 955-6. PubMed ID: 12963650
[TBL] [Abstract][Full Text] [Related]
25. Importance of triple tumor markers as biomarkers in patients with pancreatic ductal adenocarcinoma.
Takagi T; Nagai M; Nishiwada S; Terai T; Yasuda S; Matsuo Y; Doi S; Kohara Y; Sho M
Ann Gastroenterol Surg; 2023 Mar; 7(2):326-335. PubMed ID: 36998299
[TBL] [Abstract][Full Text] [Related]
26. Benefits of Conversion Surgery after Multimodal Treatment for Unresectable Pancreatic Ductal Adenocarcinoma.
Yanagimoto H; Satoi S; Yamamoto T; Yamaki S; Hirooka S; Kotsuka M; Ryota H; Ishida M; Matsui Y; Sekimoto M
Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32486418
[TBL] [Abstract][Full Text] [Related]
27. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?
Kim YC; Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Shin JH
J Gastroenterol Hepatol; 2009 Dec; 24(12):1869-75. PubMed ID: 19686409
[TBL] [Abstract][Full Text] [Related]
28. Clinical Benefits of Conversion Surgery for Unresectable Pancreatic Ductal Adenocarcinoma: A Single-Institution, Retrospective Analysis.
Mataki Y; Kurahara H; Idichi T; Tanoue K; Hozaka Y; Kawasaki Y; Iino S; Maemura K; Shinchi H; Ohtsuka T
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33801465
[TBL] [Abstract][Full Text] [Related]
29. Serum DUPAN-2 could be an Alternative Biological Marker for CA19-9 Nonsecretors with Pancreatic Cancer.
Omiya K; Oba A; Inoue Y; Kobayashi K; Wu YHA; Ono Y; Sato T; Sasaki T; Ozaka M; Sasahira N; Ito H; Saiura A; Takahashi Y
Ann Surg; 2023 Jun; 277(6):e1278-e1283. PubMed ID: 35081567
[TBL] [Abstract][Full Text] [Related]
30. Combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients.
Kanda M; Fujii T; Takami H; Suenaga M; Inokawa Y; Yamada S; Nakayama G; Sugimoto H; Koike M; Nomoto S; Kodera Y
Surg Today; 2014 Sep; 44(9):1692-701. PubMed ID: 24114022
[TBL] [Abstract][Full Text] [Related]
31. 18F-fluorodeoxyglucose positron emission tomography to indicate conversion surgery in patients with initially unresectable locally advanced pancreatic cancer.
Okano K; Suto H; Oshima M; Ando Y; Nagao M; Kamada H; Kobara H; Masaki T; Okuyama H; Okita Y; Tsuji A; Suzuki Y
Jpn J Clin Oncol; 2018 May; 48(5):434-441. PubMed ID: 29590448
[TBL] [Abstract][Full Text] [Related]
32. Serum carbohydrate antigen 125 is a significant prognostic marker in patients with unresectable advanced or recurrent gastric cancer.
Namikawa T; Kawanishi Y; Fujisawa K; Munekage E; Iwabu J; Munekage M; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K
Surg Today; 2018 Apr; 48(4):388-394. PubMed ID: 29043453
[TBL] [Abstract][Full Text] [Related]
33. Preoperative Therapy for Unresectable Locally Advanced Pancreatic Cancer for ≥6 Months Improves Prognosis After Pancreatectomy.
Matsumoto M; Shirai Y; Uwagawa T; Tsunematsu M; Sakamoto T; Fujioka S; Takahashi K; Onda S; Furukawa K; Haruki K; Hamura R; Gocho T; Ikegami T
Anticancer Res; 2023 Sep; 43(9):4097-4104. PubMed ID: 37648325
[TBL] [Abstract][Full Text] [Related]
34. Role of Serum Carcinoma Embryonic Antigen (CEA) Level in Localized Pancreatic Adenocarcinoma: CEA Level Before Operation is a Significant Prognostic Indicator in Patients With Locally Advanced Pancreatic Cancer Treated With Neoadjuvant Therapy Followed by Surgical Resection: A Retrospective Analysis.
Kato H; Kishiwada M; Hayasaki A; Chipaila J; Maeda K; Noguchi D; Gyoten K; Fujii T; Iizawa Y; Tanemura A; Murata Y; Kuriyama N; Usui M; Sakurai H; Isaji S; Mizuno S
Ann Surg; 2022 May; 275(5):e698-e707. PubMed ID: 32744820
[TBL] [Abstract][Full Text] [Related]
35. Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma.
Okada K; Kawai M; Tani M; Hirono S; Miyazawa M; Shimizu A; Kitahata Y; Yamaue H
J Hepatobiliary Pancreat Sci; 2014 Sep; 21(9):648-53. PubMed ID: 24764208
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Value of the Preoperative Tumor Marker Index in Resected Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Institution Study.
Miyata T; Hayashi H; Yamashita YI; Matsumura K; Nakao Y; Itoyama R; Yamao T; Tsukamoto M; Okabe H; Imai K; Chikamoto A; Ishiko T; Baba H
Ann Surg Oncol; 2021 Mar; 28(3):1572-1580. PubMed ID: 32804325
[TBL] [Abstract][Full Text] [Related]
37. Conversion surgery with gemcitabine plus nab-paclitaxel for locally advanced unresectable pancreatic cancer: A case report.
Okura R; Takano S; Yokota T; Yoshitomi H; Kagawa S; Furukawa K; Takayashiki T; Kuboki S; Suzuki D; Sakai N; Nojima H; Mishima T; Miyazaki M; Ohtsuka M
Mol Clin Oncol; 2018 Oct; 9(4):389-393. PubMed ID: 30214727
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy.
An X; Li YH; Lin XB; Wang FH; Feng F; Xu RH; Jiang WQ; He YJ
Ai Zheng; 2009 Mar; 28(3):286-91. PubMed ID: 19619444
[TBL] [Abstract][Full Text] [Related]
39. Preoperative serum carbohydrate antigen 125 level is an independent negative prognostic marker for overall survival in colorectal cancer.
Yang XQ; Li Y; Chen C; Peng CW; Liu SP; Liu Y
Med Oncol; 2011 Sep; 28(3):789-95. PubMed ID: 20373053
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of an inflammation-based nutritional score for patients with initially unresectable pancreatic adenocarcinoma undergoing conversion surgery following chemo-/radiotherapy.
Kokumai T; Aoki S; Mizuma M; Maeda S; Ohtsuka H; Nakagawa K; Morikawa T; Motoi F; Kamei T; Unno M
Surg Today; 2021 Oct; 51(10):1682-1693. PubMed ID: 33829334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
